When verifying a manufacturer’s WHO-GMP credentials, be alert to these warning signs:<\/p>\n\n\n\n
Before purchasing Indian generic medicines from a new manufacturer or supplier, run through this quick checklist:<\/p>\n\n\n\n
Sources: WHO Prequalification of Medicines Programme (extranet.who.int\/prequal); CDSCO official portal (cdsco.gov.in); The Economic Times (January 2026) — “Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant”; Pharmabiz (February 2026) — “CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre”; Pharmabiz (August 2026) — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI”; Indian Pharma Post and Express Pharma (September 2026) — CDSCO risk-based regulation reporting. WHO-GMP standards and scope descriptions based on WHO technical guidelines. Details sourced via Google News RSS as of September 17, 2026.<\/em><\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n India’s pharmaceutical regulatory framework has been steadily strengthening. Key developments in 2025-2026 include:<\/p>\n\n\n\n These reforms are designed to increase the reliability of Indian-manufactured medicines and make GMP verification more accessible. However, until the digital platform is fully operational, manual verification through the steps outlined above remains the best practice for buyers.<\/p>\n\n\n\n\n When verifying a manufacturer’s WHO-GMP credentials, be alert to these warning signs:<\/p>\n\n\n\n Before purchasing Indian generic medicines from a new manufacturer or supplier, run through this quick checklist:<\/p>\n\n\n\n Sources: WHO Prequalification of Medicines Programme (extranet.who.int\/prequal); CDSCO official portal (cdsco.gov.in); The Economic Times (January 2026) — “Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant”; Pharmabiz (February 2026) — “CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre”; Pharmabiz (August 2026) — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI”; Indian Pharma Post and Express Pharma (September 2026) — CDSCO risk-based regulation reporting. WHO-GMP standards and scope descriptions based on WHO technical guidelines. Details sourced via Google News RSS as of September 17, 2026.<\/em><\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n Even when a manufacturer holds WHO-GMP certification, the quality of the product you receive depends on the integrity of the supply chain. Products distributed through unverified channels may be counterfeit, improperly stored, or sourced from unauthorized secondary markets.<\/p>\n\n\n\n For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory<\/a>. Working with verified distributors reduces the risk of sourcing non-compliant or counterfeit products, regardless of the manufacturer’s GMP credentials.<\/p>\n\n\n\n\n India’s pharmaceutical regulatory framework has been steadily strengthening. Key developments in 2025-2026 include:<\/p>\n\n\n\n These reforms are designed to increase the reliability of Indian-manufactured medicines and make GMP verification more accessible. However, until the digital platform is fully operational, manual verification through the steps outlined above remains the best practice for buyers.<\/p>\n\n\n\n\n When verifying a manufacturer’s WHO-GMP credentials, be alert to these warning signs:<\/p>\n\n\n\n Before purchasing Indian generic medicines from a new manufacturer or supplier, run through this quick checklist:<\/p>\n\n\n\n Sources: WHO Prequalification of Medicines Programme (extranet.who.int\/prequal); CDSCO official portal (cdsco.gov.in); The Economic Times (January 2026) — “Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant”; Pharmabiz (February 2026) — “CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre”; Pharmabiz (August 2026) — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI”; Indian Pharma Post and Express Pharma (September 2026) — CDSCO risk-based regulation reporting. WHO-GMP standards and scope descriptions based on WHO technical guidelines. Details sourced via Google News RSS as of September 17, 2026.<\/em><\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n Beyond database checks, on-the-ground verification adds another layer of confidence. For bulk buyers and institutional procurement, consider the following:<\/p>\n\n\n\n For individual buyers and smaller pharmacies, physical verification may not be practical. In these cases, documentary verification (Steps 1-3) combined with purchasing through verified channels is the recommended approach.<\/p>\n\n\n\n\n Even when a manufacturer holds WHO-GMP certification, the quality of the product you receive depends on the integrity of the supply chain. Products distributed through unverified channels may be counterfeit, improperly stored, or sourced from unauthorized secondary markets.<\/p>\n\n\n\n For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory<\/a>. Working with verified distributors reduces the risk of sourcing non-compliant or counterfeit products, regardless of the manufacturer’s GMP credentials.<\/p>\n\n\n\n\n India’s pharmaceutical regulatory framework has been steadily strengthening. Key developments in 2025-2026 include:<\/p>\n\n\n\n These reforms are designed to increase the reliability of Indian-manufactured medicines and make GMP verification more accessible. However, until the digital platform is fully operational, manual verification through the steps outlined above remains the best practice for buyers.<\/p>\n\n\n\n\n When verifying a manufacturer’s WHO-GMP credentials, be alert to these warning signs:<\/p>\n\n\n\n Before purchasing Indian generic medicines from a new manufacturer or supplier, run through this quick checklist:<\/p>\n\n\n\n Sources: WHO Prequalification of Medicines Programme (extranet.who.int\/prequal); CDSCO official portal (cdsco.gov.in); The Economic Times (January 2026) — “Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant”; Pharmabiz (February 2026) — “CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre”; Pharmabiz (August 2026) — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI”; Indian Pharma Post and Express Pharma (September 2026) — CDSCO risk-based regulation reporting. WHO-GMP standards and scope descriptions based on WHO technical guidelines. Details sourced via Google News RSS as of September 17, 2026.<\/em><\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n For Indian manufacturers, the Central Drugs Standard Control Organisation (CDSCO) is the national regulatory authority responsible for drug licensing and GMP oversight. You can cross-check the manufacturer’s registration status through the CDSCO’s online portals.<\/p>\n\n\n\n Visit cdsco.gov.in<\/a> and look for:<\/p>\n\n\n\n The CDSCO has also announced plans to launch an end-to-end digital drug regulatory platform within 18 months (as of August 2026), which will further streamline online verification of manufacturer and product status. Until that platform is live, the existing CDSCO website and direct inquiries to state drug control authorities remain the primary verification channels.<\/p>\n\n\n\n\n Beyond database checks, on-the-ground verification adds another layer of confidence. For bulk buyers and institutional procurement, consider the following:<\/p>\n\n\n\n For individual buyers and smaller pharmacies, physical verification may not be practical. In these cases, documentary verification (Steps 1-3) combined with purchasing through verified channels is the recommended approach.<\/p>\n\n\n\n\n Even when a manufacturer holds WHO-GMP certification, the quality of the product you receive depends on the integrity of the supply chain. Products distributed through unverified channels may be counterfeit, improperly stored, or sourced from unauthorized secondary markets.<\/p>\n\n\n\n For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory<\/a>. Working with verified distributors reduces the risk of sourcing non-compliant or counterfeit products, regardless of the manufacturer’s GMP credentials.<\/p>\n\n\n\n\n India’s pharmaceutical regulatory framework has been steadily strengthening. Key developments in 2025-2026 include:<\/p>\n\n\n\n These reforms are designed to increase the reliability of Indian-manufactured medicines and make GMP verification more accessible. However, until the digital platform is fully operational, manual verification through the steps outlined above remains the best practice for buyers.<\/p>\n\n\n\n\n When verifying a manufacturer’s WHO-GMP credentials, be alert to these warning signs:<\/p>\n\n\n\n Before purchasing Indian generic medicines from a new manufacturer or supplier, run through this quick checklist:<\/p>\n\n\n\n Sources: WHO Prequalification of Medicines Programme (extranet.who.int\/prequal); CDSCO official portal (cdsco.gov.in); The Economic Times (January 2026) — “Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant”; Pharmabiz (February 2026) — “CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre”; Pharmabiz (August 2026) — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI”; Indian Pharma Post and Express Pharma (September 2026) — CDSCO risk-based regulation reporting. WHO-GMP standards and scope descriptions based on WHO technical guidelines. Details sourced via Google News RSS as of September 17, 2026.<\/em><\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n The most authoritative way to verify WHO-GMP status is through the WHO’s own databases. The WHO maintains a public Prequalification of Medicines Programme (PQP)<\/strong> website where manufacturers and products that have passed WHO inspection can be found.<\/p>\n\n\n\n Navigate to the WHO Prequalification website at extranet.who.int\/prequal<\/a>. The site provides searchable databases for:<\/p>\n\n\n\n Note the distinction between WHO-GMP certification<\/strong> and WHO prequalification<\/strong>. WHO-GMP certification confirms that the manufacturing facility meets GMP standards. WHO prequalification goes further — it involves a full evaluation of the finished product’s quality, safety, and efficacy, and is required for procurement by UN agencies. A manufacturer may hold WHO-GMP certification without having WHO-prequalified products, and both are positive signals for different reasons.<\/p>\n\n\n\n\n For Indian manufacturers, the Central Drugs Standard Control Organisation (CDSCO) is the national regulatory authority responsible for drug licensing and GMP oversight. You can cross-check the manufacturer’s registration status through the CDSCO’s online portals.<\/p>\n\n\n\n Visit cdsco.gov.in<\/a> and look for:<\/p>\n\n\n\n The CDSCO has also announced plans to launch an end-to-end digital drug regulatory platform within 18 months (as of August 2026), which will further streamline online verification of manufacturer and product status. Until that platform is live, the existing CDSCO website and direct inquiries to state drug control authorities remain the primary verification channels.<\/p>\n\n\n\n\n Beyond database checks, on-the-ground verification adds another layer of confidence. For bulk buyers and institutional procurement, consider the following:<\/p>\n\n\n\n For individual buyers and smaller pharmacies, physical verification may not be practical. In these cases, documentary verification (Steps 1-3) combined with purchasing through verified channels is the recommended approach.<\/p>\n\n\n\n\n Even when a manufacturer holds WHO-GMP certification, the quality of the product you receive depends on the integrity of the supply chain. Products distributed through unverified channels may be counterfeit, improperly stored, or sourced from unauthorized secondary markets.<\/p>\n\n\n\n For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory<\/a>. Working with verified distributors reduces the risk of sourcing non-compliant or counterfeit products, regardless of the manufacturer’s GMP credentials.<\/p>\n\n\n\n\n India’s pharmaceutical regulatory framework has been steadily strengthening. Key developments in 2025-2026 include:<\/p>\n\n\n\n These reforms are designed to increase the reliability of Indian-manufactured medicines and make GMP verification more accessible. However, until the digital platform is fully operational, manual verification through the steps outlined above remains the best practice for buyers.<\/p>\n\n\n\n\n When verifying a manufacturer’s WHO-GMP credentials, be alert to these warning signs:<\/p>\n\n\n\n Before purchasing Indian generic medicines from a new manufacturer or supplier, run through this quick checklist:<\/p>\n\n\n\n Sources: WHO Prequalification of Medicines Programme (extranet.who.int\/prequal); CDSCO official portal (cdsco.gov.in); The Economic Times (January 2026) — “Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant”; Pharmabiz (February 2026) — “CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre”; Pharmabiz (August 2026) — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI”; Indian Pharma Post and Express Pharma (September 2026) — CDSCO risk-based regulation reporting. WHO-GMP standards and scope descriptions based on WHO technical guidelines. Details sourced via Google News RSS as of September 17, 2026.<\/em><\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n A legitimate WHO-GMP-certified manufacturer should be able to provide a copy of their certificate upon request. The certificate is typically issued by a national regulatory authority (such as India’s CDSCO or a state drug control authority) or by a WHO-prequalified inspection body.<\/p>\n\n\n\n Key details to look for on the certificate:<\/p>\n\n\n\n ⚠️ Red flag: A manufacturer that cannot or will not provide a copy of their WHO-GMP certificate, or provides a certificate with missing or unclear details, should be treated with caution.<\/p>\n\n\n\n\n The most authoritative way to verify WHO-GMP status is through the WHO’s own databases. The WHO maintains a public Prequalification of Medicines Programme (PQP)<\/strong> website where manufacturers and products that have passed WHO inspection can be found.<\/p>\n\n\n\n Navigate to the WHO Prequalification website at extranet.who.int\/prequal<\/a>. The site provides searchable databases for:<\/p>\n\n\n\n Note the distinction between WHO-GMP certification<\/strong> and WHO prequalification<\/strong>. WHO-GMP certification confirms that the manufacturing facility meets GMP standards. WHO prequalification goes further — it involves a full evaluation of the finished product’s quality, safety, and efficacy, and is required for procurement by UN agencies. A manufacturer may hold WHO-GMP certification without having WHO-prequalified products, and both are positive signals for different reasons.<\/p>\n\n\n\n\n For Indian manufacturers, the Central Drugs Standard Control Organisation (CDSCO) is the national regulatory authority responsible for drug licensing and GMP oversight. You can cross-check the manufacturer’s registration status through the CDSCO’s online portals.<\/p>\n\n\n\n🔬 The Bigger Picture: India’s GMP Landscape<\/h2>\n\n\n\n
\n
⚠️ Common Red Flags to Watch For<\/h2>\n\n\n\n
\n
📝 Summary Checklist<\/h2>\n\n\n\n
\n
\n\n\n\n✅ Step 5: Use Verified Distributors<\/h2>\n\n\n\n
🔬 The Bigger Picture: India’s GMP Landscape<\/h2>\n\n\n\n
\n
⚠️ Common Red Flags to Watch For<\/h2>\n\n\n\n
\n
📝 Summary Checklist<\/h2>\n\n\n\n
\n
\n\n\n\n💡 Step 4: Physical and Documentary Verification<\/h2>\n\n\n\n
\n
✅ Step 5: Use Verified Distributors<\/h2>\n\n\n\n
🔬 The Bigger Picture: India’s GMP Landscape<\/h2>\n\n\n\n
\n
⚠️ Common Red Flags to Watch For<\/h2>\n\n\n\n
\n
📝 Summary Checklist<\/h2>\n\n\n\n
\n
\n\n\n\n📡 Step 3: Verify Through India’s CDSCO Registry<\/h2>\n\n\n\n
\n
💡 Step 4: Physical and Documentary Verification<\/h2>\n\n\n\n
\n
✅ Step 5: Use Verified Distributors<\/h2>\n\n\n\n
🔬 The Bigger Picture: India’s GMP Landscape<\/h2>\n\n\n\n
\n
⚠️ Common Red Flags to Watch For<\/h2>\n\n\n\n
\n
📝 Summary Checklist<\/h2>\n\n\n\n
\n
\n\n\n\n🔑 Step 2: Cross-Check on the WHO Prequalification Website<\/h2>\n\n\n\n
\n
📡 Step 3: Verify Through India’s CDSCO Registry<\/h2>\n\n\n\n
\n
💡 Step 4: Physical and Documentary Verification<\/h2>\n\n\n\n
\n
✅ Step 5: Use Verified Distributors<\/h2>\n\n\n\n
🔬 The Bigger Picture: India’s GMP Landscape<\/h2>\n\n\n\n
\n
⚠️ Common Red Flags to Watch For<\/h2>\n\n\n\n
\n
📝 Summary Checklist<\/h2>\n\n\n\n
\n
\n\n\n\n📋 Step 1: Locate the WHO-GMP Certificate<\/h2>\n\n\n\n
\n
🔑 Step 2: Cross-Check on the WHO Prequalification Website<\/h2>\n\n\n\n
\n
📡 Step 3: Verify Through India’s CDSCO Registry<\/h2>\n\n\n\n